SCHEMBL5126197

SCHEMBL5126197

CCCCCN1C(=O)C(OC)(OC)c2cc(SCCc3ccc(C(=O)OCC)cc3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 9/20 0.39
MAPT P10636 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 2/20 0.35
THRB P10828 1/20 0.35
PTGS1 P23219 1/20 0.34
KCNJ1 P48048 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN9A Q15858 2/20 0.34
CBX7 O95931 1/20 0.33
CDYL2 Q8N8U2 1/20 0.33
CDYL Q9Y232 1/20 0.33
CDY1; CDY1B Q9Y6F8 1/20 0.33
RARA P10276 1/20 0.33
RARB P10826 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118191 0.99 TP53 (0.39) TP53MAPTSMN1; SMN2LMNATHRB
SCHEMBL5111306 0.99 TP53 (0.39) TP53MAPTSMN1; SMN2LMNATHRB
SCHEMBL5124414 0.96 TP53 (0.39) TP53MAPTSMN1; SMN2LMNATHRB
SCHEMBL5113535 0.95 TP53 (0.38) TP53MAPTLMNATHRBPTGS1
SCHEMBL5117738 0.94 TP53 (0.37) TP53MAPTSMN1; SMN2LMNATHRB
SCHEMBL5125044 0.92 TP53 (0.40) TP53MAPTSCN9A
SCHEMBL5118471 0.90 TP53 (0.36) TP53MAPTSMN1; SMN2LMNATHRB
SCHEMBL5118444 0.90 TP53 (0.42) TP53MAPTLMNACBX7CDYL2
SCHEMBL5125008 0.87 SMN1; SMN2 (0.38) MAPTSMN1; SMN2LMNATHRBKCNJ1
SCHEMBL5114573 0.87 LMNA (0.42) TP53MAPTSMN1; SMN2LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-03 US disclosed
EP-1828124-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development (FR) 2007-09-05 EP disclosed
WO-2006063863-A1 BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004274-A1 Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA TP53 482/4885MAPT 3986/4885SMN1; SMN2 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.